Figure 3.
IK6 Enhances the In Vivo Expansion of Multipotent Repopulating Human CB Cells
(A) Experimental design.
(B) Different subsets of IK6- and control-derived human cells in the BM of primary NSG mice 26 weeks posttransplant (mean ± SEM; eight mice).
(C) Levels of human CD19+ (B) and CD33+ (GM) cells derived from IK6- and control transduced cells in the BM of individual secondary NSG mice transplanted 10 weeks previously. Limit of detection = 0.0001% based on analyses of ≥106 live cells.
(D) Frequency of secondary mice dually repopulated with control- or IK6-transduced human lymphoid and myeloid cells.
(E) Plot of data shown in (D), generated using the ELDA algorithm (Hu and Smyth, 2009), showing the natural log fraction of the nonengrafted (nonresponding) mice plotted on a linear scale on the y axis versus the transplant cell dose on the x axis.
(F) Levels of human CD19+ (B) and CD33+ (GM) cells derived from control- and IK6-transduced cells in the BM of individual secondary NSG mice transplanted 30 weeks previously.
∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.